Effects of Fenofibrate on the Safety, Toleration and Efficacy Biomarkers of CP-742,033

This study has been withdrawn prior to enrollment.

First Received on September 13, 2006. Last Updated on December 11, 2006 History of Changes

Sponsor:	Pfizer
Information provided by:	Pfizer
ClinicalTrials.gov Identifier:	NCT00376285

Purpose

The purpose of this study is to determine whether fenofibrate effects the toleration, safety, or efficacy biomarkers of CP-742,033, a drug being developed for the treatment of obesity.

Condition	Intervention	Phase
Obesity	Drug: CP-742,033 Drug: Fenofibrate	Phase I

Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Single Blind Primary Purpose: Treatment
Official Title:	A Phase 1, Randomized, Investigator and Subject Blind, Sponsor Open Study to Determine the Effects of Fenofibrate on the Safety, Toleration and Efficacy Biomarkers of CP-742,033 When Co-Administered in Otherwise Healthy Obese Adult Subjects

Resource links provided by NLM:

MedlinePlus related topics: Obesity

Drug Information available for: Procetofen

U.S. FDA Resources

Further study details as provided by Pfizer:

Primary Outcome Measures:

Toleration and safety

Secondary Outcome Measures:

Efficacy biomarkers, serum lipids

Estimated Enrollment:	30
Study Start Date:	November 2006

Eligibility

Ages Eligible for Study:	18 Years to 65 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

BMI of 30-40 kg/m2

Exclusion Criteria:

Women of childbearing potential

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00376285

Sponsors and Collaborators

Pfizer

Investigators

Study Director:

Pfizer CT.gov Call Center

Pfizer

More Information

Additional Information:

To obtain contact information for a study center near you, click here. This link exits the ClinicalTrials.gov site

No publications provided

ClinicalTrials.gov Identifier:	NCT00376285 History of Changes
Other Study ID Numbers:	A5431015
Study First Received:	September 13, 2006
Last Updated:	December 11, 2006
Health Authority:	United States: Food and Drug Administration

Additional relevant MeSH terms:

Obesity
Overnutrition
Nutrition Disorders
Overweight
Body Weight
Signs and Symptoms
Fenofibrate

Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Lipid Regulating Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on February 09, 2012